



# Biotech Daily

Thursday April 27, 2023

*Daily news on ASX-listed biotechnology companies*

- \* **ASX DOWN, BIOTECH UP: KAZIA UP 8%; USCOM DOWN 11%**
- \* **VICTORIA, SOUTH AFRICA PARTNER FOR mRNA VACCINES**
- \* **NOMINATIONS OPEN FOR \$100k GSK RESEARCH AWARD**
- \* **MEDADVISOR Q3 RECEIPTS UP 38% TO \$25.15m**
- \* **AROA RECEIPTS UP 79% TO \$49.5m**
- \* **ALCIDION Q3 RECEIPTS DOWN 6% TO \$10.45m**
- \* **IDT: PSYCHEDELICS, MARIJUANA PUSH Q3 SALES UP 26% TO \$2.1m**
- \* **TELIX PAYS \$3.6m FOR DEDICAID ARTIFICIAL INTELLIGENCE**
- \* **OSTEOPORE WINS EU MEDICAL DEVICE REGULATION**
- \* **EMYRIA REQUESTS 'PLACEMENT' TRADING HALT**
- \* **EBR \$1m, 1.8m DIRECTORS OPTIONS AGM**
- \* **TISSUE REPAIR: DR MICHAEL SILBERBERG IN; MAX JOHNSTON, CRAIG STAMP**
- \* **AROVELLA TELLS 2<sup>nd</sup> ASX QUERY: 'DATA COLLATED AFTER 39% JUMP'**

## MARKET REPORT

The Australian stock market fell 0.32 percent on Thursday April 27, 2023, with the ASX200 down 23.6 points to 7,292.7 points. Seventeen of the Biotech Daily Top 40 stocks were up, 14 fell, eight traded unchanged and one was untraded. All three Big Caps fell.

Kazia was the best, up 1.5 cents or 8.1 percent to 20 cents, with 34,663 shares traded. Avita and Proteomics climbed more than six percent; Emvision and Nova Eye improved more than four percent; Nanosonics rose 2.5 percent; Amplia, Antisense, Atomo, Micro-X, Polynovo, Prescient and Telix were up one percent or more; with Clinuvel, Genetic Signatures, Mesoblast and Neuren up by less than one percent.

Uscom led the falls, down 0.5 cents or 11.1 percent to four cents, with 38,125 shares traded. Alcidion lost 10 percent; Resonance retreated 8.3 percent; Patrys was down 6.25 percent; Starpharma fell four percent; Dimerix, Imugene and Pharmaxis were down more than three percent; Impedimed and Next Science shed more than two percent; Medical Developments, Orthocell, Resmed and Volpara were down more than one percent; with Cochlear, CSL and Pro Medicus down by less than one percent.

## VICTORIA GOVERNMENT

The Victoria Government says it will partner with South Africa to develop and manufacture low-cost, next generation, mRNA vaccines and medicines.

A media release from the Victoria Government said the partnership would “fast-track international collaboration” for mRNA vaccines and medicines, but did not disclose funding contributions.

The State Government said that the partnership included mRNA Victoria, Afrigen Biologics and the South African Medical Research Council and would include a South-Africa-based World Health Organisation mRNA Technology Transfer Hub.

The Government said the aim was to improve low-cost mRNA vaccine production capacity in low and middle-income countries and train workforces in mRNA vaccine advanced manufacturing.

The media release said that the parties agreed to share knowledge on best-practice mRNA advanced manufacturing, mRNA workforce training and development and research collaboration.

The Victoria Government said that a Afrigen Biologics and South African Medical Research Council delegation would visit research institutes including the Peter Doherty Institute for Infection & Immunity, the Burnet Institute, and Monash University's Biomedicine Discovery Institute to discuss potential collaborations.

The Government said that the South African partnership followed mRNA partnerships with the United Arab Emirates and South Korea, along with Moderna and Biontech establishing operations in Melbourne.

The Victoria Government media release said that “with global medical research over the next decade expected to be dominated by mRNA research, Melbourne has become the leading site for medical research in the Indo-Pacific, home to global innovative biotechnology companies and world-renowned medical research institutions”.

The Victoria Minister for Industry and Innovation Ben Carroll said the agreement “positions Victoria as a world leader in the mRNA industry and it ensures we play a critical role in assisting other countries to develop vaccines and medicines using this technology”.

## GLAXOSMITHKLINE

Glaxosmithkline says that nominations opened today for its \$100,000 award for research excellence.

Glaxosmithkline said the award “recognises the outstanding achievements of local medical researchers who are focused on improving human health both here and around the world”.

For apply, go to: <https://survey.gsk.com/TakeSurvey.aspx?SurveyID=n6K0m6632#>.

Nominations close on June 16, 2023.

## MEDADVISOR

Medadvisor says receipts from customers for the three months to March 31, 2023 were up 38.4 percent to \$25,154,000 compared to the previous corresponding period.

Medadvisor said receipts from its prescription reminder and vaccination booking software for the nine months were up 44.4 percent to \$87,385,000

The company said it had a cash burn of \$12,282,000 for the three months to March 31, 2023, with cash and cash equivalents of \$20,091,000 compared to \$8,813,000 in the previous corresponding period.

Medadvisor was unchanged at 22 cents.

## AROA BIOSURGERY

Aroa says receipts from customers for the year to March 31, 2023 were up 79.3 percent to \$NZ54,316,000 (\$A49,473,300) compared to previous corresponding period.

Aroa said the revenue came primarily from its sheep-stomach-derived Myriad for soft tissue repair and Ovitek and Endoform 'bio-scaffolds' as well as initial sales of its Symphony wound-closure treatment.

The company said it had a cash burn of \$1,896,000 for the three months to March 31, with cash and cash equivalents of \$NZ44,722,000 at March 31, 2023 compared to \$NZ56,165,000 at March 31, 2022.

Aroa was up 4.5 cents or 4.5 percent to \$1.055.

## ALCIDION GROUP

Alcidion says receipts from customers for the three months to March 31, 2023 were down 5.75 percent from \$11,083,000 to \$10,446,000.

Alcidion said receipts from sales and use of its hospital management systems for the nine months to March 31, 2023 were up 6.5 percent from \$27,489,000 to \$29,265,000.

The company said it had a cash burn of \$832,000 and cash and cash equivalents of \$11,087,000 at March 31, 2023, compared to \$17,472,000 at March 31, 2022.

Alcidion fell 1.1 cents or 10 percent to 9.9 cents with 19.4 million shares traded.

## IDT AUSTRALIA

IDT says sales for the three months to March 31, 2023 were up 26 percent to \$2.14 million compared to the previous three months to December 31, 2022.

IDT said that its 'specialty orals division' medical marijuana and psychedelics drove most of the increase in sales.

The company said that from July 1, 2023, the Therapeutic Goods Administration would require medical marijuana manufacturers to comply with good manufacturing practice standards and the change in regulation could help its sales, as it was good manufacturing practice certified and held all the necessary licences to manufacture medicines.

IDT was up 0.9 cents or 11.8 percent to 8.5 cents.

## TELIX PHARMACEUTICALS

Telix says it will buy Vienna's Dedicaid GmbH for EUR1.1 million (\$A1.84 million) upfront and an additional EUR1.1 million subject to US regulatory approval.

Telix said Dedicaid was a spin-off from the Medical University Vienna and had developed a "clinical decision support software" (CDSS) artificial intelligence technology with "proof-of-concept on the machine-learning methodology and applications for prostate, breast and lung cancer published in peer review journals".

Dedicaid chief executive officer Thomas Beyer said his company had "built the Dedicaid platform ... to help clinicians navigate the complex task of diagnosing and treating cancer and [delivering] state-of-the-art patient care."

Telix said the software could be used to enhance its medical imaging applications, helping with positron emission tomography (PET) and other imaging modalities.

Telix said it would submit applications to the US Food and Drug Administration and European Union regulators for the artificial intelligence platform to be designated as a "software as a medical device".

Telix was up 14 cents or 1.35 percent to \$10.53 with 1.6 million shares traded.

## OSTEOPORE

Osteopore says it has been approved for a European Union Medical Device Regulation, effective from April 24, 2023.

Osteopore said its Osteomesh, Osteoplug and Osteoplug-C products had been designated as class III medical devices, the class reserved for the highest risk medical devices.

The company said the EU Medical Device Regulation replaced the previous EU Medical Device Directive and the EU Active Implantable Medical Devices Directive.

Osteopore was up half a cent or 6.7 percent to eight cents.

## EMYRIA

Emyria has requested a trading halt "pending the release of an announcement by the company regarding a placement of securities".

Trading will resume on May 1, 2023, or on an earlier announcement.

Emyria last traded at 17 cents.

## EBR SYSTEMS

EBR says its annual general meeting will vote to issue 1,767,954 options worth \$US682,500 (\$A1,029,510) to seven directors.

EBR said shareholders would vote to issue director and chief executive officer John McCutcheon 675,000 options, exercisable at 44 US cents per US share or 65 Australian cents per Chess depository instruments (CDIs) valued at \$US202,500 and in addition to his base salary of \$US500,000, as a long-term incentive.

The company said that the meeting would vote to issue 182,159 options, worth \$US80,000 each to directors Allan Will, Karen Drexler, Dr Bronwyn Evans, Trevor Moody, Dr David Steinhaus and Dr Chris Nave, for a total of 1,092,954 options valued at \$US480,000.

EBR said the options would be exercisable at 44 US cents or 65 Australian cents and by November 21, 2031.

The company said that the meeting would vote to re-elect Dr Evans and Mr McCutcheon as directors and approve the 10 percent placement capacity.

The company said that the virtual meeting would be held Tuesday, May 23, 2023 at 9am (AEST) and Monday, May 22, 2023 at 4pm (USPDT).

EBR fell 2.5 cents or 3.1 percent to 77.5 cents.

## TISSUE REPAIR

Tissue Repair says it has appointed Dr Michael Silberberg as a non-executive director, with directors Max Johnston and Craig Stamp resigning, effective from today.

Tissue Repair said Dr Silberberg had worked in biotechnology for 20 years, and was currently Abbvie's facial aesthetics therapeutic area head was previously a physician and surgeon, and Allergan's executive medical director.

The company said Dr Silberberg held a Doctor of Medicine form from Cornell University and a Masters of Business Administration from the University of California Los Angeles.

Tissue Repair said that subject to shareholder approval Dr Silberberg would be granted 392,753 options exercisable at \$1.15 each by September 27, 2036, vesting over the next 48 months.

Tissue Repair was untraded at 20.5 cents.

## [AROVELLA THERAPEUTICS](#)

Arovella has told a second ASX 'Aware' query that it compiled data from August 2022 to April 2023 and became aware on April 15, 2023 that the data required disclosure.

Last week, Arovella responded to an ASX 'Aware' query saying that a poster featuring results from its ALA-101 for leukaemia study was printed on April 15, 2023, following a 39.3 percent price rise (BD: Apr 20, 2023).

The previous Friday, Arovella told the ASX it was not aware of any information that could explain a 39.3 percent price rise from 5.6 cents on April 11 to 7.8 cents on April 14, but said that on February 6, it had told the ASX it was scheduled to present at the American Association for Cancer Research on April 16 (BD: Apr 14, 2023).

Today, Arovella said the data collected and assembled from experiments was made available to the company "progressively during the period of August 2022 to April 2023". The company said that it "finished compiling, analyzing and interpreting the last of the new data, from experiment 5, in the morning of Saturday April 15, 2023 (AEST)".

"Shortly after this, the company was able to complete its compilation, analysis and interpretation of all the new data, on a collective basis, on the same day of April 15, 2023 (AEST)," Arovella said.

"It was only at this time ... that the company was in a position to draw meaningful and holistic conclusions from the new data [and] accordingly, it was only at this time, that the company became aware that it was in possession of information requiring disclosure under Listing Rule 3.1," Arovella said.

The company said it released an announcement prior to the start of trading on Monday, April 17, 2023 and confirmed that it was "in compliance with the Listing Rules, and in particular, Listing Rule 3.1".

Arovella was unchanged at 7.9 cents with 6.8 million shares traded.